113 related articles for article (PubMed ID: 21093172)
1. Clinical trials of a urethral dose measurement system in brachytherapy using scintillation detectors.
Suchowerska N; Jackson M; Lambert J; Yin YB; Hruby G; McKenzie DR
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):609-15. PubMed ID: 21093172
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. Permanent prostate brachytherapy in prostate glands <20 cm(3).
Mayadev J; Merrick GS; Reed JR; Butler WM; Galbreath RW; Allen ZA; Wallner KE
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1450-5. PubMed ID: 20338476
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy.
Sahgal A; Jabbari S; Chen J; Pickett B; Roach M; Weinberg V; Hsu IC; Pouliot J
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):247-54. PubMed ID: 18722275
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
6. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
7. An in vivo investigative protocol for HDR prostate brachytherapy using urethral and rectal thermoluminescence dosimetry.
Toye W; Das R; Kron T; Franich R; Johnston P; Duchesne G
Radiother Oncol; 2009 May; 91(2):243-8. PubMed ID: 18954914
[TBL] [Abstract][Full Text] [Related]
8. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
9. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125.
Bloemen-van Gurp EJ; Haanstra BK; Murrer LH; van Gils FC; Dekker AL; Mijnheer BJ; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1266-72. PubMed ID: 19665317
[TBL] [Abstract][Full Text] [Related]
10. Determination of the urethral dose in prostate brachytherapy when the urethra cannot be visualized in the postimplant CT scan.
Waterman FM; Dicker AP
Med Phys; 2000 Mar; 27(3):448-51. PubMed ID: 10757596
[TBL] [Abstract][Full Text] [Related]
11. Online in vivo dosimetry in high dose rate prostate brchytherapy with MOSkin detectors: in phantom feasibility study.
Gambarini G; Carrara M; Tenconi C; Mantaut N; Borroni M; Cutajar D; Petasecca M; Fuduli I; Lerch M; Pignoli E; Rosenfeld A
Appl Radiat Isot; 2014 Jan; 83 Pt C():222-6. PubMed ID: 23810727
[TBL] [Abstract][Full Text] [Related]
12. A plastic scintillation dosimeter for high dose rate brachytherapy.
Lambert J; McKenzie DR; Law S; Elsey J; Suchowerska N
Phys Med Biol; 2006 Nov; 51(21):5505-16. PubMed ID: 17047266
[TBL] [Abstract][Full Text] [Related]
13. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
14. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.
Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM
Radiother Oncol; 2009 May; 91(2):237-42. PubMed ID: 19167121
[TBL] [Abstract][Full Text] [Related]
15. In vivo dosimetry in the urethra using alanine/ESR during (192)Ir HDR brachytherapy of prostate cancer--a phantom study.
Anton M; Wagner D; Selbach HJ; Hackel T; Hermann RM; Hess CF; Vorwerk H
Phys Med Biol; 2009 May; 54(9):2915-31. PubMed ID: 19384000
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry.
Su Y; Davis BJ; Furutani KM; Herman MG; Robb RA
Phys Med Biol; 2007 Jun; 52(11):3105-19. PubMed ID: 17505092
[TBL] [Abstract][Full Text] [Related]
17. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
[TBL] [Abstract][Full Text] [Related]
19. A fibre optic scintillator dosemeter for absorbed dose measurements of low-energy X-ray-emitting brachytherapy sources.
Sliski A; Soares C; Mitch MG
Radiat Prot Dosimetry; 2006; 120(1-4):24-7. PubMed ID: 16782747
[TBL] [Abstract][Full Text] [Related]
20. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
